Atovaquone Chemical Structure (Ad25ab65 42aa 48f6 B5ed 247f3685d5bf 01)
Atovaquone And Proguanil Hydrochloride Tablet, Film Coated
Product Images NDC 68001-245
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Atovaquone And Proguanil Hydrochloride (NDC 68001-245). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Proguanil HCl Chemical Structure (Ad25ab65 42aa 48f6 B5ed 247f3685d5bf 02)
Atovaquone And Proguanil HCl Tablets 250_100mg 100ct Label Rev 03/17 (Image 01)
The text describes a medication called Atovaquone and Proguanil. The medication is presented in the form of tablets containing 250mg of Atovaquone and 100mg of Proguanil Hydrochloride. The recommended storage temperature of the tablets is between 59 and 86 degrees Fahrenheit. The medication should be kept in a tight, light-resistant container. There are instructions not to use the medication if the printed safety seal under the cap is broken or missing. The medication is manufactured by Glenmark Pharmaceuticals Ltd. and distributed by BluePoint Laboratories. There is also contact information for the manufacturer in Colvale-Bardez, Goa, India.*
Atovaquone And Proguanil HCl Tablets 250_100mg 24 Unit Dose Tablets Carton Label Rev 02/17 (Image 02)
The text mentions a medication, Atovaquone and Proguanil Hydrochloride Tablets, which comes in a unit dose pack of 20 (2x12) tablets. Each tablet contains 250mg Atovaquone USP and 100mg Proguanil Hydrochloride USP. The tablets are not child-resistant, and appropriate packaging should be provided when dispensing for outpatient use. The package insert should be consulted for dosage and administration. The tablets should be stored at controlled room temperature. The manufacturer is Glenmark Pharmaceuticals Ltd. from Goa, India, and the medication is distributed by BluePoint Laboratories. There is also text related to a specification, but it's not clear what it refers to.*
Image 03
This is a table that provides the recommended dosage of Atovaquone and Proguanil HCI for prevention of malaria in pediatric patients based on their weight. The dosage is given in milligrams and the regimen is either one or two tablets, depending on the child's weight. For children weighing more than 40 kg, they should take one tablet of the adult strength medication once a day.*
Image 04
Table 2 shows the recommended dosage for the treatment of acute malaria in pediatric patients based on their weight. The dosage regimen consists of Atovaquone/Proguanil Hydrochloride tablets for a period of 3 consecutive days. The recommended dosage varies according to the patient's weight, and ranges from 2 tablets for patients weighing 5 to 8 kilograms to 4 adult-strength tablets for patients weighing more than 40 kilograms.*
Image 05
Image 06
This appears to be a label for tablets containing Atovaquone and Proguanil hydrochloride. The tablets are 250 mg / 100 mg and manufactured by Glenmark Pharmaceuticals Ltd. The label also provides the size of the packaging which is 110U x 2201 x 89N. There is mention of "SANE SIZE ARTWORK", but it is difficult to determine what this refers to.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
